{"article_title": "Goldman Sachs Upgrades Alere, Downgrades Quest", "article_keywords": ["upgraded", "rating", "structure", "goldman", "downgrades", "sachs", "shares", "grow", "quest", "streamlined", "upgrades", "today", "firms", "alere", "york"], "article_url": "https://www.genomeweb.com/business-news/goldman-sachs-upgrades-alere-downgrades-quest", "article_text": "NEW YORK (GenomeWeb) \u2013 Goldman Sachs today upgraded shares of Alere to a Buy rating, but downgraded Quest Diagnostics' shares to Neutral.\n\nIn a research note, analyst Isaac Ro upgraded Alere from a previous Neutral rating and said that he believes that Alere's new management has brought focus to the firm's new products, streamlined its cost structure, and reduced its debt. As a result, he anticipates revenues to grow about 6 percent between the firm's fiscal years 2015 and 2018, and EPS to grow 17 percent during the same period.", "article_metadata": {"description": "The investment bank noted the potential of Alere's new MDx platforms, but said that Quest's potential could suffer in comparison to its competitor LabCorp.", "generator": "Drupal 7 (http://drupal.org)", "og": {"site_name": "GenomeWeb", "description": "The investment bank noted the potential of Alere's new MDx platforms, but said that Quest's potential could suffer in comparison to its competitor LabCorp.", "title": "Goldman Sachs Upgrades Alere, Downgrades Quest", "url": "https://www.genomeweb.com/business-news/goldman-sachs-upgrades-alere-downgrades-quest", "image": "https://www.genomeweb.com/sites/default/themes/siteskin/inc/images/ogimg-default2.png", "type": "article"}, "twitter": {"url": "https://www.genomeweb.com/business-news/goldman-sachs-upgrades-alere-downgrades-quest", "card": "summary", "title": "Goldman Sachs Upgrades Alere, Downgrades Quest"}, "HandheldFriendly": "True", "msvalidate.01": "589DA07A6166C67D948C23FD502C6942", "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "NEW YORK (GenomeWeb) \u2013 Goldman Sachs today upgraded shares of Alere to a Buy rating, but downgraded Quest Diagnostics' shares to Neutral.\nAs a result, he anticipates revenues to grow about 6 percent between the firm's fiscal years 2015 and 2018, and EPS to grow 17 percent during the same period.\nIn a research note, analyst Isaac Ro upgraded Alere from a previous Neutral rating and said that he believes that Alere's new management has brought focus to the firm's new products, streamlined its cost structure, and reduced its debt."}